A study found a spread of type 2 diabetes (T2D) through blood transfusions or toxic meat as a result of misshapen protein bodies. The protein seeds are similar to those associated with the spreading of mad cow disease to humans from cattle. Authors say type 2 diabetes (T2D) is easier to spread compared to brain diseases (such as mad cow disease) with the consumption of "rogue" proteins present in animal products. Spreading of brain diseases is not easy as the brain contains the blood-brain barrier (BBB), which separate fluid in the central nervous system and brain from circulating blood.
Islet amyloid polypeptide (IAPP) present in cattle and other large animals are structurally similar to humans. An earlier study found deposits of misshapen protein or islet amyloid polypeptide (IAPP) in more than 90 percent of the patients with diabetes. Islet amyloid polypeptide (IAPP) protein seeds are similar in humans who carry mad cow disease. Researchers speculate the spread of rogue proteins in species.
The researchers have conducted experiments with genetically modified mice models by injecting them with toxic clusters. They observed signs of type 2 diabetes (T2D) symptoms within weeks. They also observed signs of type 2 diabetes when toxic clusters were added to pancreatic tissue of a healthy human in a dish. There is no evidence to show that type 2 diabetes (T2D) is contagious and the mechanism behind the development of type 2 diabetes (T2D) in mice models will apply to humans. Now the research team is investigating the possibility of acquiring type 2 diabetes (T2D) with the consumption of "rogue" proteins present in animal products.
Senior author of the study was Christopher J. Soto, Associate Professor of Psychology, Colby College, Waterville, Maine, United States. The study was published on August 1, 2017, in the Journal of Experimental Medicine. Title of the article was "Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism."
A study by the researchers at the University College London, United Kingdom, show the prevention of Parkinson's disease with exenatide. A 48-week study with either placebo or with a weekly injection of exenatide was conducted on 62 patients with Parkinson's disease. The patients under the study did not stop the regular treatment of Parkinson's disease. A 12-week washout period was included in the trial.
The study shows significant improvement in the Parkinson's disease severity scores in patients under exenatide and worsening disease severity scores in patients under placebo. The results show a promising treatment option for Parkinson's disease with exenatide diabetes drug. As the current study was small, researchers say a long-term study is required with larger participants before considering exenatide diabetes drug as a viable treatment option for Parkinson's disease.
The study was funded by the Michael J. Fox Foundation for Parkinson's Research, New York, United States. Co-author of the study was Dr. Thomas Foltynie, Ph.D., Professor of Neurology, National Hospital for Neurology and Neurosurgery, University College London. The study was published on August 3, 2017, in The Lancet journal. Title of the article was "Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial."
Exenatide : Once-Weekly exenatide is marketed as Bydureon, Byetta. It is a glucagon-like peptide-1 receptor agonist (GLP-1), used to lower high blood sugar levels by patients with type 2 diabetes (T2D). Exenatide lowers blood glucose levels by increasing insulin secretion, reducing appetite and preventing the action of glucagon.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.